U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}
structurally diverse
Status:
US Previously Marketed
Source:
Valerian U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Valerian U.S.P.
Source URL:

Class:
STRUCTURALLY DIVERSE

Status:
First marketed in 1921
Source:
calcium pentobarbital
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)



Pentobarbital belongs to the class of a short-acting barbiturate is used as sedatives, hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks; preanesthetics and anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Pentobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. All of these effects are associated with marked decreases in GABA-sensitive neuronal calcium conductance (gCa). The net result of barbiturate action is acute potentiation of inhibitory GABAergic tone. Barbiturates also act through potent (if less well characterized) and direct inhibition of excitatory AMPA-type glutamate receptors, resulting in a profound suppression of glutamatergic neurotransmission.
Status:
US Previously Marketed
Source:
Somnafac by Smith Miller
(1972)
Source URL:
First approved in 1962
Source:
BIPHETAMINE-T by STRASENBURGH
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)



Methaqualone is a depressant that modulates the activity of the GABA receptors in the brain and nervous system. It promotes relaxation, sleepiness and sometimes a feeling of euphoria. It causes a drop in blood pressure and slows the pulse rate. These properties are the reason why it was initially thought to be a useful sedative and anxiolytic. Common side effects of Methaqualone include dizziness, nausea, vomiting, diarrhea, abdominal cramps, fatigue, itching, rashes, sweating, dry mouth, tingling sensation in arms and legs, seizures and its depressant effects include reduced heart rate and respiration. The drug became banned in many countries and was withdrawn from many markets in the early 1980s.
Status:
US Previously Marketed
Source:
DELVINAL by MSD
(1961)
Source URL:
First approved in 1940
Source:
Delvinal by Sharp & Dohme (MSD)
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Conditions:

VINBARBITAL, a barbiturate derivative, is a hypnotic drug. Also, it was used for analgesia and anesthesia in obstetrics.
Status:
US Previously Marketed
Source:
hexobarbital
(1933)
Source URL:
First marketed in 1933
Source:
hexobarbital
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Hexobarbital or hexobarbitone, (sold both in acid and sodium salt, brand name Evipan, and Tobinal), is a barbiturate derivative having hypnotic and sedative effects. It was used in the 1940s and 1950s as an agent for inducing anesthesia for surgery, as well as a rapid-acting, short-lasting hypnotic for general use, and has a relatively fast onset of effects and short duration of action. It was also used to murder women prisoners at Ravensbruck Concentration Camp. Modern barbiturates (such as Thiopental) has largely supplanted the use of hexobarbital as an anesthetic, as they allow for better control of the depth of anesthesia. Hexobarbital is still used in some scientific research. Hexobarbital binds at a distinct binding site associated with a Cl- ionophore at the GABA-A receptor, increasing the duration of time for which the Cl- ionophore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Status:
US Previously Marketed
First marketed in 1929
Source:
secobarbital
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)



Secobarbital sodium, a barbiturate, is FDA approved for the treatment of insomnia and for pre-anesthetic use. This drug binds at a distinct site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. Adverse reactions are drowsiness, lethargy, hangover, paradoxical excitement in elderly patients, somnolence. Rifampin may decrease secobarbital levels by increasing metabolism.
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (RACEMIC)

Proxibarbal is a non-sedative barbiturate with a specific anti-serotonin and anti-histamine effect, due to enzyme induction of serotoninase and histaminase. Its lack of unpleasant side-effects. Proxibarbal exists in ring-chain tautomeric equilibrium with the two diastereomers of valofan. Proxibarbal is metabolized to a five-membered lactone. Its only barbituric property is its ability to induce enzymes that destroy a surplus of neurohormones and rid people of their neurovegetative sufferings, including migraine and other types of vascular headache. Side effects are: dizziness, drowsiness, dyspepsia, allergic reactions. Proxibarbal enhances the effects of other depriving agents, including alcohol.
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)

CHLORAL HYDRATE ANTIPYRINE is a 1:1 mixture of antipyrine with chloral hydrate. It was used as a hypnotic drug known as HYPNAL in the late 19th century.